Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 23, 2008
Last updated: March 24, 2017
Last verified: March 2017
This is a multicenter, open-label, randomized, parallel group comparison study to verify the clinical equivalency of the old formulation (50 mcg as mometasone furoate [MF] in 50 μL of solution per spray) to the new formulation (50 mcg as MF in 100 μL of solution per spray) in patients with perennial allergic rhinitis.

Condition Intervention Phase
Rhinitis, Allergic, Perennial
Drug: mometasone furoate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Clinical Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Change in 4 nasal symptom score (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) from baseline at Week 2. [ Time Frame: After 2 weeks of treatment ]

Secondary Outcome Measures:
  • Change in each nasal symptom (sneezing attack, rhinorrhea, nasal congestion, and nasal itching). [ Time Frame: After 2 weeks of treatment ]
  • Overall improvement [ Time Frame: 2 weeks ]
  • Adverse events [ Time Frame: From initial day of treatment until treatment is stopped. ]
  • Laboratory tests [ Time Frame: At 7 or more days before treatment start, and after 2 weeks of treatment ]

Enrollment: 102
Actual Study Start Date: February 1, 2005
Study Completion Date: April 1, 2005
Primary Completion Date: April 1, 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: New Formulation Group Drug: mometasone furoate
The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
Other Names:
  • Nasonex
  • SCH 32088
Active Comparator: Old Formulation Group Drug: mometasone furoate
The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
Other Names:
  • Nasonex
  • SCH 32088


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients of mongoloid race residing in Japan who satisfy all of the following criteria:

    • Patients having symptoms of perennial allergic rhinitis of moderate or severe degree, according to the classification of severity in the guidelines for the treatment of nasal allergy (partial revision) as well as a score of at least 4 in the score of 4 nasal symptoms, at the time of obtaining informed consent and during the pretreatment observation period.
    • Patients with a positive skin reaction test or specific IgE antibody quantitation, and with a positive cytological examination of nasal discharge (eosinophils) or nasal challenge test.
    • Outpatients who are at least 16 years of age at the time of informed consent obtained.
    • Male or female.
    • Patients who have the ability to give written informed consent (informed consent of the guardian must also be obtained for patients younger than 20 years).
    • Patients who can keep nasal allergy diary without fail.

Exclusion Criteria:

  • Patients with coexisting tuberculous disease or lower respiratory tract infection, or patients who, at the time of registration, have acute upper respiratory tract infection, acute pharyngitis, acute amygdalitis etc.
  • Patients with coexisting infections or systemic mycosis for which there are no effective antibiotics.
  • Patients with unhealed nasal septum ulcers, nasal surgery scar, or nasal trauma.
  • Patients with a history of hypersensitivity to steroids or mometasone furoate.
  • Patients who are pregnant or nursing or who may be pregnant and patients or patients' partners who desire to become pregnant during the study period.
  • Patients with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension or other serious coexisting diseases and whose general condition is poor.
  • Patients also allergic to pollen and the pollen release season occurs during the study period.
  • Patients with vasomotor rhinitis or eosinophilic rhinitis.
  • Patients with a nasal condition which may interfere with efficacy evaluation of the investigational product.
  • Patients who develop disease affecting nasal symptoms during the pretreatment observation period, i.e., during the 7 days before actual registration.
  • Patients who are participating or have participated in a clinical trial of another investigational drug within 120 days (4 months) before the day of the informed consent for this study.
  • Patients for whom the period of discontinuation of previous treatment effective for allergic rhinitis before the start of the investigational product administration is not sufficient or who cannot avoid its use.
  • Patients receiving specific desensitization therapy or nonspecific modulation therapy or who had just discontinued such therapies within 90 days (3 months) before providing consent to this study (unless such therapies are ongoing as maintenance therapy and had been started 180 days [6 months] or more before consent to this study).
  • Other patients judged inappropriate for study by the investigator or subinvestigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

T. Ishikawa et. al; Practica otologica. Suppl.123 Page1-18 (2008.12) -Japanese language journal

Study Data/Documents: CSR Synopsis  This link exits the site

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00779740     History of Changes
Other Study ID Numbers: P04419
Study First Received: October 23, 2008
Last Updated: March 24, 2017

Additional relevant MeSH terms:
Rhinitis, Allergic
Rhinitis, Allergic, Perennial
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Mometasone Furoate
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents processed this record on April 28, 2017